After pausing a trial for a Moderna-partnered cystic fibrosis candidate due to subpar tolerability, Vertex Pharmaceuticals ...

UCB has struck a deal to acquire Candid Therapeutics for $2 billion upfront, hijacking a planned reverse merger with Rallybio ...

For Jake Becraft, Ph.D., the future of America’s biomedical innovation isn’t just playing out in the lab—it's being shaped by ...

Windward Bio is in full sail with a $165 million crossover financing to push its long-acting anti-TSLP antibody into phase 3, ...

A phase 3 trial of Celcuity’s pan-PI3K/mTOR inhibitor has hit its primary endpoint, clearing the biotech to file a second ...

After some tough feedback from the FDA on the path forward for its lead gene therapy, Passage Bio has launched a strategic ...

Mirum Pharmaceuticals is prepping for a new FDA approval application after its small molecule volixibat successfully ...

A pivotal study of a Takeda primary immunodeficiency disease (PID) asset has hit its primary endpoint, demonstrating ...

Ever since psychedelic medicine in the U.S. was stymied by government action, the field has been steadily clawing its way ...

Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an ...

Incyte’s povorcitinib has scored a pair of phase 3 wins for a skin condition, although analysts noted the oral JAK inhibitor ...

The FDA today announced a new initiative to allow its reviewers to access information from clinical trials in real time, with ...